Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) Short Interest Update

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) was the recipient of a large decrease in short interest in the month of July. As of July 15th, there was short interest totalling 28,900 shares, a decrease of 93.7% from the June 30th total of 457,800 shares. Currently, 0.2% of the company’s stock are sold short. Based on an average trading volume of 590,400 shares, the short-interest ratio is currently 0.0 days.

Theriva Biologics Trading Down 6.1 %

Shares of TOVX traded down $0.02 on Thursday, reaching $0.27. The stock had a trading volume of 105,422 shares, compared to its average volume of 319,187. The company has a quick ratio of 3.60, a current ratio of 3.60 and a debt-to-equity ratio of 0.01. Theriva Biologics has a 12-month low of $0.20 and a 12-month high of $0.70. The stock has a market cap of $4.70 million, a PE ratio of -0.24 and a beta of 1.38.

Theriva Biologics (NYSEAMERICAN:TOVX) last announced its quarterly earnings data on Tuesday, May 7th. The company reported ($0.30) EPS for the quarter.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.